The annual increase in blood urea was determined in 253 patients attending a hypertension clinic. In twothirds ofpatients there was a rise in blood urea during treatment, which was not related to blood pressure control when measured in the standing position, or to the level of serum potassium. The blood urea level was increased during guanethidine administration but this appeared reversible on stopping treatment. Methyldopa and reserpine therapy did not increase the blood urea, and diuretics and bethanidine produced only minor nonsignificant changes. These findings are discussed in relation to the different actions of these hypotensive agents.
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It is important to monitor renal function in hypertension, as renal failure accounts for up to 30 per cent of the deaths in hypertensive patients treated in hospital (Breckenridge, Dollery, and Parry, 1970) . The retrospective investigation to be described was carried out to determine the effect of blood pressure control, therapy given, and serum potassium on renal function in patients attending the Hammersmith Hospital hypertension clinic.
Methods
The records of all patients attending the Hammersmith clinic were examined for a 3-month period. If a patient had attended the clinic for more than 5 years and had at least 4 estimations of blood urea, the annual increment in blood urea was computed. The method of estimating the increment in blood urea is being described in detail elsewhere (Bulpitt, I974) .
The patients had been followed for a mean of 7 years with, on average, I2 blood urea measurements. These measurements were distributed lognormally and therefore the logarithm of blood urea was employed in the calculations. Many patients had more than one estimation of blood urea in a calendar year, in which case the average log urea was calculated for each year a patient was followed. The annual increment in this log urea was calculated for each patient using a linear regression technique.
The average serum potassium was computed for each year, provided measurements were available for at least 4
Received iI September 1973. years and excluding a small number of patients with asthma who were receiving steroid therapy. The mean of the yearly serum potassium results for a patient gave the average level of serum potassium for that patient.
A subset of II9 patients who attended over a 6-week period had a record made of all previous standing blood pressure measurements, excluding the year of presentation to the clinic, in order to give an estimate of the influence of blood pressure control. The average standing systolic and diastolic pressures were computed for each calendar year, excluding the year the patient first attended the clinic, and from these results average systolic and diastolic pressures were calculated for the whole followup period. The average log blood urea for each patient was also computed using all the blood urea measurements for that patient. Diagnoses, average age during follow-up, and details of therapy given were recorded. Therapy was subdivided into drugs given for more than two-thirds of the study period and drugs given for less than this time. Blood urea was estimated by the diacetyl monoxime method and the serum potassium by flame photometry, all measurements being made on plasma samples in the Department of Chemical Pathology, Royal Postgraduate Medical School. All blood pressures had been taken using a standard mercury manometer, after about one minute in the standing position, and the diastolic blood pressure almost always was taken at the point of muffling ofsound.
Results
The records of 253 patients were studied. One hundred and seventy-six patients had essential hypertension (go women, 86 men) and 77 were Table i summarizes the first analysis. The patients were divided into those who had never received a particular therapy and those who received the therapy for more than two-thirds of the follow-up time. When compiling this Table, drug combinations were allowed and patients receiving one drug were often receiving other hypotensive agents as well. The average blood urea, annual increment in log urea, and systolic and standing diastolic pressures are listed. The number of patients contributing to each result is also given. The average blood urea was moderately raised in the group receiving guanethidine compared with the group not receiving this drug (46-8 mg/ioo ml against 37.4 mg/Ioo ml; P < o-oi). The guanethidine group also had a significantly raised standing systolic pressure (i6Ix8 mmHg against I1O-9 mmHg; P < o-oi), and the annual increase in log blood urea was highest in this group (o-oo95 per annum), but not significantly different from the group not receiving guanethidine (o-oo65 per annum). The average blood urea while taking methyldopa, 38-5 mg/ioo ml, a diuretic, 38-7 mg/ioo ml, reserpine 35-O mg/too ml, and bethanidine 41-o mg/Ioo ml, were not significantly different from the groups not taking these drugs. Similarly the mean log urea increments for these drug groups were not significantly different from the corresponding comparison groups.
Effect of therapy
Considering only patients who received guanethidine, i8 had at least 3 blood urea measurements both before and during guanethidine therapy, and 7 had at least 3 measurements of blood urea both during and after guanethidine therapy. The i8 patients showed an average rise in blood urea of i ii mg/ioo ml after receiving guanethidine which was significant at the i per cent level. The 7 patients showed a non-significant fall in blood urea of 2-2 mg/ Ioo ml on stopping guanethidine. Using all the blood urea results in patients given guanethidine, there were i44 measurements before the drug was started, giving an average of 36-3 mg/iOO ml; 375 measurements during guanethidine therapy, average 513 mg/ioo ml, and 77 measurements after stopping guanethidine, average 402 mg/too ml.
Effect of serum potassium level Table 2 gives the mean blood urea for each sex according to the average level of serum potassium.
The average blood urea in female patients was lower than in male patients and was independent of the level of serum potassium. Similarly, there was no significant relation between the male average blood urea and the average serum potassium. There is circumstantial evidence that potassium depletion may predispose to pyelonephritis (Muehrcke and McMillan, i963; Woods et al., group.bmj (Fourman, McCance, and Parker, I956). The groups with a low serum potassium during follow-up were therefore examined for evidence of an increased annual increment in log blood urea (Table 2 ). There was no above average increment in the I7 patients with an average serum potassium equal to or less than 3.4 mN, and no significant increase in urea increment for 89 patients with an average serum potassium between 3-5 and 3-9 mN. The group with a relatively high mean serum potassium of 4.5 tO 4.9 mN did not show, on average, a positive annual increment in blood urea, but this group contained only I3 patients.
Effect of blood pressure control Table 3 gives the correlation coefficient between annual log urea increment and the standing diastolic and systolic blood pressure for the four groups, male and female, essential and 'secondary' hypertension. There was no significant positive linear relation (MacKay and MacKay, 1927) , and urea diffuses out of the renal tubules. However, the estimation of blood urea was routinely made during the years of study, and many patients were on methyldopawhich renders autoanalyser results inaccurate for urinary creatinine and possibly plasma creatinine measurements (Madocks et al., I973) . The blood urea measurements should therefore have given a worthwhile estimate of glomerular filtration in this longterm study on hypertensive patients. Two-thirds of the treated patients with essential hypertension had an increase in blood urea with time, and increases with age found in the normal population may be of a somewhat lower order of magnitude than in these hypertensive patients (Bulpitt, 1974; Lewis and Alving, I938; Josephson and Dahlberg, 1952) .
Certified deaths from hypertensive heart disease and malignant hypertension have been steadily falling in England and Wales but not those from hypertensive renal disease (Registrar General, I973). It is, therefore, relevant that this study failed to demonstrate a significantpositiverelationbetween the standing blood pressure in treated patients and the rise in blood urea, especially as the average standing systolic pressure ranged from I20 tO 193 mmHg and the diastolic pressure from 76 to i i6 mmHg. The relation between the lying blood pressure and the increase in blood urea remains to be determined.
The excessive rise in blood urea in treated hypertensives could not be explained on the basis of hypokalaemia. In all, 229 patients received a potassium-losing diuretic for some of their follow-up period and I70 received potassium supplements. In spite of potassium therapy, the mean of the serum potassium level was only 3-8 mN, and 17 patients had an average serum potassium of less than 3-5 mN. It was reassuring that at these levels of serum potassium there was no evidence ofan excessive rise in bloodurea.
The only drug associated with a higher than average increase in blood urea was guanethidine. Guanethidine has been reported to produce a fall in blood urea in 60 per cent of cases (Bhatt and Naik, I966) ; a slight rise in most cases with a normal presenting blood urea but a fall in patients presenting with a high blood urea (Singh and Haritwal, I965a); a rise in 58 per cent of patients (Leishman and Sandler, I967); a fall in 20 per cent of patients and no mention of any increases (Mehta, Bansal, and 
